

Form 1449		U.S. Department of Commerce Patent and Trademark Office			ATTY. DOCKET NO. 2444-101		SERIAL NO. 09/601,444
LIST OF MATERIALS CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT Esther H. CHANG et al.		
					FILING DATE 02 August 2000		GROUP
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Q		Aoki, K et al. "Liposome-mediated <i>in Vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity", <i>Cancer Research</i> , Sept. 1, 1995; 55:3810-3816					
		Dzau, V.J. et al. "Fusogenic viral liposome for gene therapy in cardiovascular diseases", <i>Proc. Natl. Acad. Sci. USA</i> , October 1996; 93:11421-11425					
		Feero, W.G. et al. "Selection and use of ligands for receptor-mediated gene delivery to myogenic cells", <i>Gene Therapy</i> , 1997; 4:664-674					
		Filion, M.C. et al. "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells", <i>Biochimica et Biophysica Acta</i> , 1997; 1329:345-356					
		Grimaldi, S. et al. "Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection", <i>Res. Virol.</i> , 1997; 148:177-180					
		He, Y. et al. "Growth Inhibition of Human Papillomavirus 16 DNA-positive Mouse Tumor by Antisense RNA Transcribed from U6 Promoter", <i>Cancer Research</i> , September 15, 1997; 57:3993-3999					
		Lappalainen, K. et al. "Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells", <i>Antiviral Research</i> , 1994; 23:119-130					
EXAMINER <i>DAN</i>			DATE CONSIDERED <i>7/9/02</i>				
EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form 1449		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. 2444-101	SERIAL NO. 09/601,444
LIST OF MATERIALS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Esther H. CHANG et al.		
		FILING DATE 02 August 2000	GROUP	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
<i>a</i>		Lavigne, C. et al. "Enhanced Antisense Inhibition of Human Immunodeficiency Virus Type 1 in Cell Cultures by DLS Delivery System", <i>Biochemical and Biophysical Research Communications</i> , 1997; 237:566-571		
		Lee, R.J. et al. "Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer", <i>The Journal of Biological Chemistry</i> , April 5, 1996; 271(14):8481-8487		
		Morishita, R. et al. "Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer", <i>J. Cardiovasc. Pharmacol. Therapeut.</i> , 1996; 2(3):213-222		
		Plank, C. et al. "Activation of the Complement System by Synthetic DNA Complexes: A Potential Barrier for Intravenous Gene Delivery", <i>Human Gene Therapy</i> , Aug. 1, 1996; 7:1437-1446		
		Renneisen, K. et al. "Inhibition of Expression of Human Immunodeficiency Virus-1 <i>In Vitro</i> by Antibody-targeted Liposomes Containing Antisense RNA to the env Region", <i>The Journal of Biological Chemistry</i> , Sept. 25, 1990; 265(27):16337-16342		
		Ropert, C. et al. "Oligonucleotides Encapsulated in pH Sensitive Liposomes are Efficient Toward Friend Retrovirus", <i>Biochemical and Biophysical Research Communications</i> , Mar. 16, 1992; 183(2):879-885		
		Seth, P. et al. "Adenovirus-mediated Gene Transfer to Human Breast Tumor Cells: An Approach for Cancer Gene Therapy and Bone Marrow Purging", <i>Cancer Research</i> , Mar. 15, 1996; 56:1346-1351		
		Wagner, E. et al. "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle", <i>Proc. Natl. Acad. Sci. USA</i> , Sept. 1992; 89:7934-7938		
		Xu, M. et al. "Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity", <i>Human Gene Therapy</i> , Jan. 20, 1997; 8:177-185		
		Zelphati, O. et al. "Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes", <i>Antiviral Research</i> , 1994; 25:13-25		
		Zelphati, O. et al. "Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms", <i>Nucleic Acids Research</i> , 1994; 22(20):4307-4314		
<i>Dm</i>		EXAMINER	DATE CONSIDERED	<i>7/9/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

#7

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

JUL 02 2002

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  		<i>Complete if Known</i>	
		Application Number	09/601,444
		Filing Date	January 4, 2001
		First Named Inventor	Esther H. Chang
		Group Art Unit	1632
		Examiner Name	Dave Trong Nguyen
Sheet	1	of	1
Attorney Docket Number			

## **U.S. PATENT DOCUMENTS**

~~RECEIVED~~

JUL 08 2002

~~TECH CENTER 1600/2900~~

## **FOREIGN PATENT DOCUMENTS**

**Examiner  
Signature**

Dash

Date  
Considered

7/11/02

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.